ReviewFrontiers in pharmacology2021
Augmented Renal Clearance: What Have We Known and What Will We Do?
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 32 citations in OpenAlex.
- Augmented renal clearance: from pathophysiological mechanisms to clinical implications and research perspectives.Renal failure · 2026Review
- Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study.British journal of clinical pharmacology · 2026Article
- Serum-Creatinine-Estimated Augmented Renal Clearance is Associated with Marked Weight Loss after Severe Traumatic Brain Injury.Neurocritical care · 2026Article
- Population Pharmacokinetics of Amikacin in Non-Neonatal Pediatric Patients: A Scoping Review.European journal of drug metabolism and pharmacokinetics · 2026Article
- Impact of Febrile State on Vancomycin Clearance in Pediatric Patients: Insights From Population Pharmacokinetic Modeling.Pharmaceutical research · 2026Article
- Vancomycin Exposure Dynamics and Clinical Outcomes in Critically Ill Patients: A Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2026Article
- Impact of eGFR estimation methods on drug dosing in pediatric ICU: a study of serum creatinine vs. cystatin C.European journal of clinical pharmacology · 2026Article
- Evaluation of the Effect of Mechanical Ventilation on the Pharmacokinetic Parameters of Vancomycin in Intensive Care Patients: A Prospective Cohort Study.Journal of research in pharmacy practice · 2026Article
- The "Dilution Effect" of Augmented Renal Clearance on the Prognostic Utility of NT-proBNP in Patients with Severe Traumatic Brain Injury.International journal of general medicine · 2026Article
- Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC Study.Neurocritical care · 2025Observational
- Population pharmacokinetics of levetiracetam in Chinese adult epilepsy patients with varying renal function: exposure simulation and individualized dosing adjustments.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization.Therapeutic advances in drug safety · 2025Article
- A real-world study of the optimal cut-off value for vancomycin trough concentration associated with outcomes in children infected with drug-resistant Gram-positive bacteria.Frontiers in pediatrics · 2025Article
- Development and validation of the prediction score for augmented renal clearance in critically Ill Japanese adults.Journal of pharmaceutical health care and sciences · 2024Article
- Retrospective Study of Factors Affecting the Accuracy of Predicting Vancomycin Concentrations in Patients Aged 75 Years and Above.Medicina (Kaunas, Lithuania) · 2024Article
- Population pharmacokinetics of meropenem in critically ill patients.Open medicine (Warsaw, Poland) · 2024Article
- Optimize Vancomycin Dose in Surgical Ward Patients with Augmented Renal Clearance Determined by Chronic Kidney Disease Epidemiology Collaboration Equation.Infection and drug resistance · 2024Article
- Article
- Article
- Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time.Open forum infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Augmented renal clearance (ARC) is a phenomenon of increased renal function in patients with risk factors. Sub-therapeutic drug concentrations and antibacterial exposure in ARC patients are the main reasons for clinical treatment failure. Decades of increased research have focused on these phenomena, but there are still some existing disputes and unresolved issues. This article reviews information on some important aspects of what we have known and provides suggestion on what we will do regarding ARC. In this article, we review the current research progress and its limitations, including clinical identification, special patients, risk factors, metabolism, animal models and clinical treatments, and provide some promising directions for further research in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.